Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Daxor has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Daxor achieved revenue of $1.3M and an EBITDA of n/a.
Daxor expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Daxor valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $6.3M | $1.3M | n/a | n/a | XXX |
Gross Profit | n/a | n/a | n/a | XXX | XXX |
Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
EBITDA | n/a | n/a | n/a | n/a | XXX |
EBITDA Margin | NaN% | NaN% | NaN% | NaN% | XXX |
Net Profit | $4.7M | $5.2M | $0.3M | XXX | XXX |
Net Margin | 75% | 404% | NaN% | XXX | XXX |
Net Debt | $3.0M | $1.2M | $0.8M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 7, 2025, Daxor's stock price is $7.
Daxor has current market cap of $36.1M, and EV of $37.8M.
See Daxor trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$37.8M | $36.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 7, 2025, Daxor has market cap of $36.1M and EV of $37.8M.
Daxor's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Daxor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Daxor and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $37.8M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDaxor's NTM/LTM revenue growth is n/a
Daxor's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Daxor's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Daxor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Daxor and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 24% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 78% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Electromed | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daxor acquired XXX companies to date.
Last acquisition by Daxor was XXXXXXXX, XXXXX XXXXX XXXXXX . Daxor acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Daxor founded? | Daxor was founded in 1971. |
Where is Daxor headquartered? | Daxor is headquartered in United States of America. |
How many employees does Daxor have? | As of today, Daxor has 12 employees. |
Who is the CEO of Daxor? | Daxor's CEO is Mr. Michael R. Feldschuh. |
Is Daxor publicy listed? | Yes, Daxor is a public company listed on NAS. |
What is the stock symbol of Daxor? | Daxor trades under DXR ticker. |
When did Daxor go public? | Daxor went public in 1992. |
Who are competitors of Daxor? | Similar companies to Daxor include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem. |
What is the current market cap of Daxor? | Daxor's current market cap is $36.1M |
Is Daxor profitable? | Yes, Daxor is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.